Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

ZetaChain: The Private Memory Layer for AI

View original at globenewswire.com
ZetaChain: The Private Memory Layer for AI Key takeaways: ZetaChain launched Anuma, its first consumer AI product: the private AI that remembers, with one encrypted memory across every AI you use and access controlled by you.ZETA is the token that powers Anuma and the network underneath it: unlocking models and agents,…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Only 9% of consumers pay for more than one AI subscription because trying a new model means giving up everything the old one learned

    60% confidence
  • Generative AI hit 53% global adoption in three years, faster than the PC or the internet

    60% confidence
  • The leading AI labs are tightening their hold on their best models, locking developers and users into proprietary ecosystems

    60% confidence
  • ChatGPT crossed 900 million weekly active users in February 2026, up from 400 million a year earlier

    60% confidence
  • In financial services, non-human identities now outnumber human employees by roughly 96 to 1, and they have no portable way to prove who they are or who they work for

    60% confidence
  • The largest hyperscale cloud companies will spend more than half a trillion dollars on AI capital expenditures in 2026, an estimate revised higher every quarter

    60% confidence
  • The next era of AI will not be defined by whoever ships the best model, but by apps and infrastructure that give users ownership, control, and continuity across all of them

    60% confidence
  • Cloudflare reports more than a billion HTTP 402 responses served every day

    60% confidence
  • ZetaChain's four-year cross-chain infrastructure mission produced 12 million users and 240 million transactions

    60% confidence
  • Anuma crossed 60,000 users in its first month, demonstrating that private, user-owned AI is the start of the next major consumer layer

    60% confidence
  • 40% of enterprise applications will include task-specific AI agents by the end of 2026, up from less than 5% in 2025

    60% confidence
  • x402 adoption is rapidly growing, processing more than 170 million transactions in six months

    60% confidence
  • Blockchains are the missing infrastructure that AI agents need

    60% confidence
  • Every AI chatbot conversation lives on a company's server and users only have a license to use it, not true ownership

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com